| Project/Area Number |
20591533
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAUE Hiroki 和歌山県立医科大学, 医学部, 教授 (20191190)
IWAHASHI Makoto 和歌山県立医科大学, 医学部, 講師 (70244738)
NAKAMORI Mikihito 和歌山県立医科大学, 医学部, 講師 (10322372)
MATSUDA Kenji 和歌山県立医科大学, 医学部, 助教 (30398458)
NAKA Teiji 和歌山県立医科大学, 医学部, 学内助教 (00453184)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 樹状細胞 / TGF-β / adenovirus vector / siRNA / 免疫遺伝子治療 |
|---|
| Research Abstract |
Recently, several studies have shown that TGF-βproduced from tumor cells would inhibit cytotoxic activity of cytotoxic T lymphocytes(CTLs) and increase the number of regulatory T cells(Treg) in tumor local environment. Therefore, as administration of TGF-βsiRNA would inhibit production of TGF-βin tumor environment, it would be expect that antitumor effect of immunotherapy using dendritic cells(DCs) could be enhanced. This study was examined whether antigen-specific CTL responses and therapeutic immunity could be enhanced by genetically-modified DCs expressing CEA antigen and TGF-βsiRNA. Consequently, an effective antitumor immune response was not induced because of unstable expression of TGF-βsiRNA. Further investigation is needed to optimize this vaccine therapy to achieve the obvious benefit in clinical application.
|
